BeiGene announced its results for the six months ended June 30, 2026, with total revenue increasing by 32.3% year-on-year. The global sales of its flagship product, BRUKINSA® (zanubrutinib), reached US$2.342 billion, a year-on-year increase of 34.5%, serving as the core performance engine. During the reporting period, the company had multiple new drugs approved by the FDA, reached a collaboration agreement with Revolution Medicines, and made an additional investment of US$300 million to expand its manufacturing and R&D center in the United States.